Blue Route

About Blue Route

Blue Route Technologies for Neurodevelopment is a digital health company founded in 2025 in Spain. The company is developing an AI-powered platform, La Ruta Azul, for the early screening, diagnosis, and personalized digital therapy of neurodevelopmental disorders, with an initial focus on Autism Spectrum Disorder (ASD). The platform integrates evidence-based clinical standards, behavioral video analysis using artificial intelligence, and adaptive digital therapeutics.

The development of Blue Route was a direct response to the significant delays in the diagnosis of conditions like ASD, where parental concerns often arise between 18 and 22 months, but a definitive diagnosis may not occur until ages 3 or 4. This delay can consume a critical window for impactful intervention. Blue Route aims to bridge this structural gap in the healthcare system by providing a tool for early, objective, and accessible risk signal identification. The solution involves a guided initial autoscreening for families, AI-driven analysis of behavioral patterns from videos, and the creation of personalized intervention pathways. Winning the AI & mHealth Challenge served as a key validation point for the company's concept.

Blue Route operates on a hybrid B2C and B2B business model. It partners with families, healthcare providers, and institutions to improve patient outcomes and increase access to neurodevelopmental care. The company is also exploring strategic partnerships and the integration of third-party technologies, such as assessing a potential collaboration with Cognoa, whose Canvas Dx is an FDA-approved AI diagnostic tool for autism. Looking ahead, Blue Route plans to secure CE marking as a medical device in Europe after its AI models are fully implemented and clinically validated.